Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2005 3
2006 9
2007 11
2008 4
2009 6
2010 6
2011 19
2012 11
2013 14
2014 7
2015 7
2016 5
2017 10
2018 11
2019 13
2020 17
2021 22
2022 16
2023 25
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Among authors: liberopoulos e. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Author's Reply.
Barkas F, Liberopoulos E, Rizos EC. Barkas F, et al. Among authors: liberopoulos e. J Cardiol. 2020 Feb;75(2):217. doi: 10.1016/j.jjcc.2019.08.009. Epub 2019 Sep 20. J Cardiol. 2020. PMID: 31543379 Free article. No abstract available.
Hypocholesterolemia.
Moutzouri E, Elisaf M, Liberopoulos EN. Moutzouri E, et al. Among authors: liberopoulos en. Curr Vasc Pharmacol. 2011 Mar;9(2):200-12. doi: 10.2174/157016111794519354. Curr Vasc Pharmacol. 2011. PMID: 20626336
Oxidized phospholipids and lipoprotein(a): An update.
Koutsogianni AD, Liberopoulos E, Tellis K, Tselepis AD. Koutsogianni AD, et al. Among authors: liberopoulos e. Eur J Clin Invest. 2022 Apr;52(4):e13710. doi: 10.1111/eci.13710. Epub 2021 Nov 27. Eur J Clin Invest. 2022. PMID: 34837383 Review.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Canagliflozin and Amputation Risk: Evidence So Far.
Papadokostaki E, Rizos E, Tigas S, Liberopoulos EN. Papadokostaki E, et al. Among authors: liberopoulos en. Int J Low Extrem Wounds. 2020 Mar;19(1):21-26. doi: 10.1177/1534734619878090. Epub 2019 Nov 8. Int J Low Extrem Wounds. 2020. PMID: 31698973 Review.
195 results